Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.

Lachowiez CA., Borthakur G., Loghavi S., Zeng Z., Kadia TM., Masarova L., Takahashi K., Tippett GD., Naqvi K., Bose P., Jabbour E., Ravandi F., Daver NG., Garcia-Manero G., Stoilova B., Vyas P., Kantarjian HM., Konopleva M., Dinardo CD.

DOI

10.1200/jco.2020.38.15_suppl.7500

Type

Journal article

Publisher

American Society of Clinical Oncology (ASCO)

Publication Date

2020-05-20T00:00:00+00:00

Volume

38

Pages

7500 - 7500

Total pages

0

Keywords

32 Biomedical and Clinical Sciences, 3211 Oncology and Carcinogenesis, Pediatric, Orphan Drug, Clinical Research, Pediatric Cancer, Childhood Leukemia, Hematology, Genetics, Clinical Trials and Supportive Activities, Cancer, Rare Diseases, 6.1 Pharmaceuticals

Permalink More information Close